Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | The impact of emicizumab prophylaxis on caregivers’ burden for patients with hemophilia A

Eman Hassan • 3 Apr 2022
BSH 2022
Hemophilia Antibodies Emicizumab

Eman Hassan, MD, Birmingham Children’s Hospital, Birmingham, UK, gives an overview of some results from a study which assessed the impact of emicizumab prophylaxis on caregivers’ burden for pediatric patients with hemophilia A. Dr Hassan first explains the convenient route of administration of emicizumab, as well as its high efficacy and safety profile, which all provide numerous benefits. Following this, Dr Hassan discusses the main aims of this study, and some interesting results, which demonstrate that caregivers’ burden is reduced in all domains when emicizumab is administered. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from Eman Hassan

0:51
Unmet need in hemophilia A: breakthrough bleeds
Eman Hassan • 3 Apr 2022
1:23
The present and future of hemophilia A treatment
Eman Hassan • 3 Apr 2022

Related Videos

1:08
The current landscape of hemophilia treatment: an update from ASH 2023
Glaivy Batsuli • 10 Dec 2023
1:18
Unmet needs in hemophilia treatment
Glaivy Batsuli • 10 Dec 2023
1:11
Improving outcomes for hemophilia patients through the implementation of gene therapies
Evelien Krumb • 12 Dec 2023
1:27
The impact of emicizumab on the hemophilia treatment landscape
Glaivy Batsuli • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals